The challenge of post-implementation surveillance for novel meningococcal vaccines.

Matthew D Snape, Duccio Medini, Scott A Halperin, Lisa DeTora, Jonathan Drori, E Richard Moxon

Oxford Universities Hospitals NHS Trust, United Kingdom. matthew.snape@paediatrics.ox.ac.uk

Vaccine 2012 May 30

filter terms:

Novel serogroup B meningococcal vaccines are currently in late stage development and may be used in mass immunisation campaigns over the coming years. This represents an exciting development in the prevention of childhood meningitis, however monitoring the impact of these vaccines on meningococcal disease epidemiology will provide significant challenges. Although designed to prevent serogroup B meningococcal disease the vaccine antigens are not serogroup specific, creating the potential for multiple definitions of vaccine effectiveness and vaccine failure. Copyright © 2011 Elsevier Ltd. All rights reserved.

Citation

Matthew D Snape, Duccio Medini, Scott A Halperin, Lisa DeTora, Jonathan Drori, E Richard Moxon. The challenge of post-implementation surveillance for novel meningococcal vaccines. Vaccine. 2012 May 30;30 Suppl 2:B67-72